Transparency and Ethics
Ethical guidelines
FIFARMA
We comply with the strict ethical and transparency guidelines of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Our commitment as a pharmaceutical industry is focused on contributing to the co-creation of solutions that promote more sustainable health ecosystems and provide greater opportunity for early access to innovative medicines and treatments to improve the lives of millions of patients in Latin America and the Caribbean.
Our activity is governed by the highest standards of transparency and ethics on the part of our members, which allows us to interact with the different actors involved in the health ecosystems, identifying, and preventing conflicts of interest and respecting their independence of judgment.
In this way, we can actively and responsibly participate in the public debate, providing transparent and ethical access to data and evidence for better decision making, allowing the implementation of innovative solutions where the patient and his or her wellbeing are the focus and priority of the industry.
Code of good practices
FIFARMA and its members comply with the Code of Good Practices of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). First developed in 1981, the Code has been revised in recent decades. Its most recent update was in 2019, which ensures that practices in the pharmaceutical research and development industry are governed by ethical standards aligned with evolving societal expectations and, promptly, the current goals of the industry in the region.
This document contains our commitment to integrity, providing a practical guide for the pharmaceutical industry in its interactions with the different actors in the health sector.
Our commitment beyond codes of conduct
At FIFARMA, we believe that it is not enough to adhere to and implement a code of good practices to guarantee integrity in the health sector. Therefore, as a Federation we have contributed to improving health for the benefit of the population, promoting integrity and accountability in the health ecosystem in the Latin American region, collaborating in the drafting, adherence and implementation of "Business Principles For Promoting Integrity in The Pharmaceutical Sector", a regional multi-sectoral industry initiative led by Transparency International UK.
This document contains our commitment to integrity, providing a practical guide for the pharmaceutical industry in its interactions with the different actors in the health sector.
ACCESS TO INFORMATION
Observatorio Regional y Health Innovation Outlook
One of the roles we have as a Federation is to make relevant and contrasted information on the health sector in Latin America and the Caribbean available to ecosystem stakeholders to enable the development of innovation and the growth of the pharmaceutical industry. This is why the Observatorio Regional y el Health Innovation Outlook are working to present open, contrasted, and truthful data that will allow us to strengthen decision-making processes.
Our activity is governed by the highest standards of transparency and ethics on the part of our members, which allows us to interact with the different actors involved in the health ecosystems, identifying, and preventing conflicts of interest and respecting their independence of judgment.
In this way, we can actively and responsibly participate in the public debate, providing transparent and ethical access to data and evidence for better decision making, allowing the implementation of innovative solutions where the patient and his or her wellbeing are the focus and priority of the industry.
Integrity Principles
At FIFARMA, we are firmly committed to working in favor of strengthening the pharmaceutical industry in the region, the well-being of patients and the economic and social development of the countries, always observing quality standards and good practices in terms of transparency and ethics.